EXHIBIT 10.4

FOR IMMEDIATE RELEASE

Contacts:   Urologix:
            Fred B. Parks, Chairman and CEO
            Todd E. Paulson, Chief Financial Officer
            Brooks West, Director, Marketing & Business Development
            (763) 475-1400

  Urologix Announces Agreement for the Development of Real-Time Imaging System

      Minneapolis - August 2, 2005 - Urologix(R), Inc. (NASDAQ:ULGX), has
entered into a co-development agreement with ProUroCare Medical, Inc. (OTC BB:
PRRC.OB), and Rensselaer Polytechnic Institute to develop a real-time
temperature imaging system, ProUroVision(TM), to be utilized with Urologix'
Cooled ThermoTherapy(TM) treatment of benign prostatic hyperplasia (BPH) as well
as potential new indications.

      Cooled ThermoTherapy is a single, minimally invasive in-office treatment
that uses targeted microwave energy combined with a unique cooling mechanism to
provide safe, effective and lasting relief from BPH symptoms. BPH, also known as
enlarged prostate disease, is a non-cancerous condition that can make urination
difficult or painful and is common in men over the age of 50.

      "We look forward to working with the researchers at Rensselaer Polytechnic
Institute and the scientific and engineering team at ProUroCare," said David
Montecalvo, Urologix vice president of product development and operations. "If
successful, we will be able to provide accurate discrete temperature
measurements at multiple points in the prostate. This information will allow our
treating physicians to view an image of the patients' prostate during the
procedure, showing the heating effect and associated tissue necrosis resulting
from our Cooled ThermoTherapy treatment in real-time."

      Maury Taylor, ProUroCare chairman and chief executive officer, commented,
"We are excited about working with Urologix, the leader in the treatment of BPH.
We believe this proprietary technology will prove to enhance the physician's
vision of the Cooled ThermoTherapy treatment. This relationship ensures that
this newly developed technology, if effective, will receive optimal distribution
in the urology marketplace."

      Fred Parks, Urologix chairman and chief executive officer, added, "This
development opportunity exemplifies our commitment to providing efficient,
efficacious and economical treatment options for physicians and the
ever-increasing number of BPH patients. Further, it advances our plans to expand
our core technology into new disease states and patient populations."

<PAGE>

About BPH

      BPH, also known as enlarged prostate disease, is a non-cancerous condition
in which prostate cells begin to increase in number. This growth, a normal part
of aging process, causes the gland to compress the urethra making urination
difficult or painful. Although it is not known exactly what causes an enlarged
prostate, it is a common condition generally affecting men over age 50. In fact,
more than half of all men over age 60 have BPH symptoms. If left untreated, BPH
can lead to more serious health problems, such as urinary retention, bladder
stones, urinary infections or kidney damage. BPH affects more than 23 million
men worldwide.

About ProUroCare

      ProUroCare Medical Inc., based in Minneapolis, is developing innovative
diagnostic and treatment approaches for male prostate disease and other
genito-urinary related conditions. The company is primarily focused on tactile
sensor technology and the ProUroScan(TM) system that is capable of identifying
tissue abnormalities and mapping the prostate to assist the physician's
diagnostic process. In addition, ProUroCare is developing the ProUroVision(TM)
proprietary vision technology for thermal therapy systems to aid in the
treatment of prostate-related diseases.

About Urologix

      Urologix, Inc., based in Minneapolis, develops, manufactures and markets
minimally invasive medical products for the treatment of urological disorders.
The company has developed and offers non-surgical, anesthesia-free,
catheter-based treatments that use a proprietary cooled microwave technology for
the treatment of BPH. Urologix markets its products under the Targis(R) and
Prostatron(R) names. Both systems utilize Cooled ThermoTherapy(TM) - targeted
microwave energy combined with a unique cooling mechanism to protect healthy
tissue and enhance patient comfort - and provide safe, effective, lasting relief
of the symptoms of BPH.